A novel therapeutic approach for anaplastic thyroid cancer through inhibition of LAT1

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Anaplastic thyroid cancer (ATC) is a rapidly progressing and fatal disease with limited treatment options.
• The MYC protein is highly expressed in ATC and its inhibition with JQ1 has shown therapeutic potential.
• MYC regulates L-neutral amino acid transporter 1 (LAT1), suggesting LAT1 inhibition as a therapeutic strategy.

Purpose of the Study:

• To evaluate the efficacy of JPH203, a LAT1 inhibitor, as a potential treatment for anaplastic thyroid cancer.
• To investigate the mechanism of action of JPH203 in ATC cell lines and xenograft models.

Main Methods:

• In vitro cell-based studies using three human ATC cell lines.
• In vivo efficacy evaluation using a xenograft model bearing human ATC cells.
• Analysis of mTOR signaling pathways and cell cycle progression.

Main Results:

• LAT1 protein is highly expressed in human ATC but not in non-cancerous thyroid tissue.
• JPH203 significantly inhibited ATC cell proliferation by suppressing mTOR signaling and blocking cell cycle progression (G0/G1 to S phase).
• JPH203 demonstrated tumor growth inhibition and size reduction in vivo, consistent with mTOR and cell cycle pathway suppression.

Conclusions:

• LAT1 is a promising therapeutic target for anaplastic thyroid cancer.
• JPH203, a LAT1 inhibitor, exhibits significant preclinical efficacy against ATC.
• LAT1 inhibitors represent strong candidates for controlling ATC, addressing a critical unmet medical need.